Pfizer Stock News

Covid has made it clear: the likes of Pfizer, in thrall to shareholders, only really care about their huge profits Pfizer has had an exceptionally good pandemic. Today it announced that its Covid-19 vaccine brought in $37bn billion last year , making it easily the most lucrative medicine in any given year in history. That isn’t all. For a company that was until recently the least trusted company in the least trusted industrial sector in the United States, Covid-19 has been a PR coup. Pfizer has become a household name over the last 12 months. The company was toasted on nights out in Tel Aviv , and there are cocktails named after its vaccine in bars across the world. The US president referred to Pfizer’s chief executive, Albert Bourla, as a “ good friend ”, and the great man parked his jet next to Boris Johnson’s at last year’s G7 summit in Cornwall. Nick Dearden is director of Global Justice Now Continue reading…

Pfizers COVID-19 vaccine brought in a bumper income of nearly $37 billion in sales for 2021, the products first full year on the market, though Pfizers revenue forecasts for 2022 came in below analysts expectations, sending its shares down by over 5 percent. Called Comirnaty, the companys two-dose COVID-19 vaccine generated $36.78 billion in revenue []

Pfizers COVID-19 vaccine brought in a bumper income of nearly $37 billion in sales for 2021, the products first full year on the market, though Pfizers revenue forecasts for 2022 came in below analysts expectations, sending its shares down by over 5 percent. Called Comirnaty, the companys two-dose COVID-19 vaccine generated $36.78 billion in revenue []

Although Pfizer raised its forecast for the vaccine, developed with Germany''s BioNTech SE, by $1 billion to $32 billion, the drugmaker cautioned that final sales for the year may not top that figure. Last year, the company increased its COVID vaccine sales forecast several times as it signed more deals to supply it around the world.

Although Pfizer raised its forecast for the vaccine, developed with Germany''s BioNTech SE, by $1 billion to $32 billion, the drugmaker cautioned that final sales for the year may not top that figure. Last year, the company increased its COVID vaccine sales forecast several times as it signed more deals to supply it around the world.

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- Sickle Cell Disease Treatment Market Facts at a Glance- Total Pages: 120 Companies: 10+ – Including Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA , Novartis AG, and Pfizer Inc. among others. Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape; COVID impact & recovery analysis Segments: Indication (sickle cell anemia and others) Geographies: APAC ( China and India ), Europe ( Germany and UK), North America (US), South America , and MEA Didn''t Find What You Were Looking For? Customize Report- Don''t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- Sickle Cell Disease Treatment Market Facts at a Glance- Total Pages: 120 Companies: 10+ – Including Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA , Novartis AG, and Pfizer Inc. among others. Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape; COVID impact & recovery analysis Segments: Indication (sickle cell anemia and others) Geographies: APAC ( China and India ), Europe ( Germany and UK), North America (US), South America , and MEA Didn''t Find What You Were Looking For? Customize Report- Don''t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

The S&P 500 and the Nasdaq declined on Tuesday as disappointing earnings from Pfizer and declines in megacap technology names added to jitters ahead of inflation data this week that could spark bets on quicker interest rate hikes. Pfizer Inc fell 5.3% after the drugmaker''s full-year sales forecast for its COVID-19 vaccine and antiviral pills fell short of Wall Street estimates. Facebook-owner Meta Platforms fell 1.4% after billionaire investor Peter Thiel decided to step down from the company''s board. The stock is down for a fourth session after its bleak forecast wiped out billions of dollars in market value last week. Other high-growth stocks like Google-owner Alphabet Inc and Amazon.com Inc fell 1% each, while big banks like Bank of America Corp and JPMorgan Chase & Co jumped 2.5% each. "We''ve got a rising interest rate environment which we haven''t seen since 2018 and there are a lot of investors in high growth names that continue to see weakness," said Dennis Dick, a trader at Bright Trading LLC in Las Vegas. "You''re going to see money rotate to lower multiple names and more value-oriented market." Seven of the eleven major S&P 500 sectors declined, with energy leading the fall.

The S&P 500 and the Nasdaq declined on Tuesday as disappointing earnings from Pfizer and declines in megacap technology names added to jitters ahead of inflation data this week that could spark bets on quicker interest rate hikes. Pfizer Inc fell 5.3% after the drugmaker''s full-year sales forecast for its COVID-19 vaccine and antiviral pills fell short of Wall Street estimates. Facebook-owner Meta Platforms fell 1.4% after billionaire investor Peter Thiel decided to step down from the company''s board. The stock is down for a fourth session after its bleak forecast wiped out billions of dollars in market value last week. Other high-growth stocks like Google-owner Alphabet Inc and Amazon.com Inc fell 1% each, while big banks like Bank of America Corp and JPMorgan Chase & Co jumped 2.5% each. "We''ve got a rising interest rate environment which we haven''t seen since 2018 and there are a lot of investors in high growth names that continue to see weakness," said Dennis Dick, a trader at Bright Trading LLC in Las Vegas. "You''re going to see money rotate to lower multiple names and more value-oriented market." Seven of the eleven major S&P 500 sectors declined, with energy leading the fall.

Pfizer also expects $22 billion in sales of Paxlovid, the company''s pill for Covid-19, in 2022

~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of aerosolized viruses; initially targeting SARS CoV-2 ~ ~ Technologies developed in the laboratories of Yale University Professors Mark Saltzman and Akiko Iwasaki ~ ~ Preclinical data demonstrates intranasal PACE/Spike mRNA and Spike recombinant protein boosters induce robust mucosal immunity in the nasosinus and upper respiratory tract and protect against lethal doses of SARS-CoV-2 variants when administered after systemic immunization with Pfizer''s mRNA COVID-19 vaccine ~ NEW HAVEN, Conn., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Xanadu Bio, a privately held company focusing on next generation delivery of mRNA and other nucleic acids, today announced a broad exclusive license agreement from Yale University for a next generation polymeric nanoparticle delivery platform known as PACE. Additionally, the company has executed options with Yale University for the intranasal delivery of PACE/Spike mRNA and Spike recombinant proteins for the development of mucosal immunity in the nasosinus.